Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
快速连接

白皮书

White Paper on Sugammadex API

2023

White Paper on Sugammadex API

Tech Sheet on Pregabalin API

2023

Tech Sheet on Pregabalin API

Product Alert – Niraparib API

2023

Product Alert – Niraparib API

Product Alert – Tucatinib API

2023

Product Alert – Tucatinib API

Product Alert – Relugolix API

2023

Product Alert – Relugolix API

Product Alert – Pazopanib API

2023

Product Alert – Pazopanib API

Tech Sheet on Midostaurin API

2023

Tech Sheet on Midostaurin API

Tech Sheet on Tofacitinib Citrate

2023

Tech Sheet on Tofacitinib Citrate

Tech Sheet on Ibrutinib

2022

Tech Sheet on Ibrutinib

Tech Sheet on Linagliptin

2022

Tech Sheet on Linagliptin

Tech Sheet on Dutasteride

2022

Tech Sheet on Dutasteride

New Product Alert – Ruxolitinib Phosphate

2022

New Product Alert – Ruxolitinib Phosphate

Tech Sheet on Voriconazole

2022

Tech Sheet on Voriconazole

Tech Sheet on Nilotinib Hydrochloride

2022

Tech Sheet on Nilotinib Hydrochloride

Addressing the presence of mutagenic Azido impurities in Sartan APIs

2022

Addressing the presence of mutagenic Azido impurities in Sartan APIs

Co-Crystal and Customized Particle Size for Early Launch Opportunity of Siponimod API

2022

Co-Crystal and Customized Particle Size for Early Launch Opportunity of Siponimod API

New Product Alert – Lumateperone Tosylate API

2022

New Product Alert – Lumateperone Tosylate API

Tech sheet: Dr. Reddy's Bempedoic Acid API Offerings

2022

Tech sheet: Dr. Reddy's Bempedoic Acid API Offerings

Tech sheet: Dr. Reddys Olaparib API Offerings

2022

Tech sheet: Dr. Reddy's Olaparib API Offerings

Tech sheet: Dr. Reddy's Enzalutamide API Offerings

2022

Tech sheet: Dr. Reddy's Enzalutamide API Offerings

Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API

2022

Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API

Our Peptide API Capabilities and Services throughout the product life cycle

2022

Our Peptide API Capabilities and Services throughout the product life cycle

Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings

2022

Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings

Tech Sheet – Dr. Reddy’s Fexofenadine API offerings

2022

Tech Sheet – Dr. Reddy’s Fexofenadine API offerings

Tech Sheet - Dr. Reddy’s Azacitidine API offerings

2022

Tech Sheet - Dr. Reddy’s Azacitidine API offerings

Tech Sheet - Dr. Reddy’s Ramipril API offerings

2022

Tech Sheet - Dr. Reddy’s Ramipril API offerings

Tech Sheet: Gemcitabine API

2021

Tech Sheet: Gemcitabine API

Tech Sheet: Dr. Reddy’s Abiraterone Acetate API offerings

2021

Tech Sheet: Dr. Reddy’s Abiraterone Acetate API offerings

Remdesivir

2021

瑞德西韦（Remdesivir）系由瑞迪博士（Dr.Reddy’s）在吉利德（Gilead）许可下研发：

Whitepaper : Dr.Reddy's 2 DG- A promising treatment in hospitalized COVID-19 patients

2021

白皮书： 瑞迪博士的2 DG - 一种对住院的新冠病毒病患者来极具前景的治疗方法

Techsheet: Dr.Reddy's Lenvatinib API offerings

2021

技术表： 瑞迪博士的乐伐替尼（Lenvatinib）原料药产品

Bempedoic acid - a near term launch opportunity for generic pharma manufacturers

2021

贝派地酸（Bempedoic acid） - 仿制药制造商近期推出市面的机遇

ROXADUSTAT - a multipronged development strategy

2021

罗沙司他（ROXADUSTAT）- 多管齐下的发展战略

Dr.Reddy's Apremilast API and finished formulation offerings.

2021

瑞迪博士的阿普斯特片（Apremilast）原料药和成品配方产品。

Dr. Reddy’s Fosaprepitant API offerings

2021

瑞迪博士的福沙吡坦（Fosaprepitant）原料药产品

Apixaban API – ready-to-compress granules and finished dosage forms

2021

阿哌沙班（Apixaban）原料药 - 易压缩颗粒和成品剂型

Apalutamide API – an attractive NCE-1 opportunity for generic pharma companies

2021

阿帕鲁胺（Apalutamide）原料药 - 对仿制药公司极具吸引力的NCE-1机遇

Colloidal Iron Complex Formulations – Understanding and Developing the Process

2021

胶体铁络合物（Colloidal Iron Complex）配方 - 认识和发展流程

Rivaroxaban from Dr.Reddy’s: Full basket offerings of API and Finished formulations

2021

瑞迪博士的利伐沙班（Rivaroxaban）： 完整的原料药和成品配方产品

Dr. Reddy's Mirabegron API offering in both alpha and amorphous form

2021

瑞迪博士提供的阿尔法型和非晶型（Mirabegron） 原料药

Palbociclib – how a novel process development approach provides IP advantages

2021

帕博西尼（Palbociclib） - 新流程开发方法如何提供知识产权优势

Dr. Reddy's Elagolix API offering leverages a well rounded Quality by Design approach

2020

瑞迪博士的恶拉戈利（Elagolix ）原料药提供了全面的质量源于设计方法

Sacubitril/Valsartan (LCZ696) – Bringing yet another advantage through innovative API offerings

2020

沙库必曲/缬沙坦（Sacubitril/Valsartan）（LCZ696） - 通过创新的原料药产品带来另一个优势

Dr. Reddy’s Flow Chemistry experts share their perspectives in panel discussion of Chemistry Today

2020

瑞迪博士流动化学专家在《今日化学》（Chemistry Today）小组讨论会上分享了他们的观点

A closer look on how Dr. Reddy's met the stringent regulatory requirement of genotoxic impurities in Ranolazine

2020

进一步了解瑞迪博士如何满足雷诺嗪（Ranolazine）中基因毒性杂质的严格监管要求

Famotidine and Nizatidine APIs: NDMA controlled, customized particle distribution, supply chain security

2020

法莫替丁（Famotidine）和尼扎替丁（Nizatidine）原料药： 受控的亚硝基二甲胺（NDMA），定制的颗粒分布，安全的供应链

Meeting the New Regulatory Requirements in Sartan API Production

2019

满足沙坦（Sartan）原料药生产的新法规要求

免责声明

本目錄中的任何信息（包括對任何產品或服務的任何引用）均不構成銷售要約，或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是，只要存在此類監管豁免，就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估，並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途，但可用於第 107A 節。

X
Connect & collaborate with us at

 

Meet us in BOOTH 4C30

24th-26th October 2023    Fira Barcelona Gran Via, Spain

Sign up